Eplerenone in the Management of Abdominal Aortic Aneurysms
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Weakening and expansion of the main abdominal artery (abdominal aortic aneurysm, AAA) is a
common problem in older Australians. The majority of AAAs are small (<55 mm) and affect
90,000 individuals in Australia and 4.5 million world-wide. Currently, the only treatment
available for AAA is surgery. However, surgical therapies are not effective for small AAAs,
and these patients undergo a program of repeat imaging and consultation to monitor the size
of the aneurysm and symptoms.
This proposal is aimed at addressing the urgent need to identify a medical treatment able to
limit progression of AAAs.
The study design and rationale are based on strong preclinical evidence supporting the value
of eplerenone (an agent indicated for treatment of heart failure) in limiting AAA
progression. If proved effective, this medication would:
1. Reduce the number of patients requiring costly surgery
2. Reduce the number of surgery related deaths and complications
3. Provide a therapy suitable for the rapidly expanding elderly age group who have AAAs.
Phase:
Phase 4
Details
Lead Sponsor:
Bayside Health
Collaborators:
Baker Heart and Diabetes Institute Baker IDI Heart and Diabetes Institute